Zepbound with insurance often runs $25–$200 per month after savings; without coverage, cash prices run $349–$1,300 by dose and program.
Shopping for weekly tirzepatide injections can feel like chasing a moving target. Plan rules, deductibles, step edits, and dose changes all shape what you pay. This guide lays out clear ranges, the levers that change the bill, and practical steps to cut costs starting with your next fill.
Quick Ranges By Coverage Type
Use this table as your fast checkpoint. It lists common plan types, what many members see at the register, and the main hoop each plan sets.
| Plan Type | Typical Monthly Out-Of-Pocket | What Usually Drives It |
|---|---|---|
| Large Employer/Union | $25–$200 after a savings card; $150–$450 if no card | Formulary tier, prior auth, and whether your PBM offers a copay cap (some cap at ~$200) |
| Small Employer | $100–$500; some plans exclude weight-loss use | Exclusions are common; appeals and medical exception letters can help |
| ACA/Marketplace | $150–$600 if covered; list price if excluded | Many Bronze/Silver plans apply the full deductible before coinsurance kicks in |
| Medicare Part D / MA-PD | $0–$200 if covered for obstructive sleep apnea; otherwise excluded for weight loss | Part D excludes drugs “when used for weight loss,” but coverage can apply for other FDA-labeled uses like OSA |
| Medicaid (by state) | $0–$50 if the state PDL covers it; list price if not | Coverage varies by state program and indication; prior auth common |
| Self-Pay Via Manufacturer | $349–$499 via LillyDirect vials (dose and timing rules apply) | Flat cash price programs for single-dose vials outside insurance |
| Retail Cash (no programs) | $995–$1,300+ | Pharmacy cash price for pens varies by location and dose |
What “Covered” Really Means For Zepbound Costs
Even when a plan lists tirzepatide for weight management on its formulary, the real out-of-pocket depends on three switches: prior authorization, tier/coinsurance, and where you are in the deductible year.
Prior Authorization And Clinical Criteria
Most commercial plans require a request from your prescriber that shows BMI and a qualifying risk condition, or an approved labeled use. Many policies also require a trial of lifestyle changes and a set weight-loss response to continue treatment. Insurers publish these rules in utilization policies and drug-quantity limits. Cigna, for instance, maintains prior authorization criteria and quantity-limit sheets for weight-management GLP-1s that include tirzepatide; these documents outline BMI thresholds, re-auth timing, and supply limits.
Tier, Coinsurance, And Deductible Timing
Some pharmacy benefits place Zepbound on a specialty tier with coinsurance (say, 20%–40%) while others use a flat copay. If you have a high-deductible plan, early-year fills can be closer to list price until the deductible is met, then drop to the copay or coinsurance share.
Copay Caps And PBM Add-Ons
Several benefit managers offer optional add-ons that cap your share for weight-loss GLP-1s. One widely reported cap sets the member share at about $200 per month for covered brands, with the amount counting toward your deductible and out-of-pocket max.
When Medicare Or Medicaid Pays
Federal programs have separate rules. Part D plans typically exclude drugs when used for weight loss under the statute that governs Part D benefits. Coverage can apply when a product has an FDA-approved use that isn’t weight loss. That matters here because tirzepatide now carries an indication for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside its weight-management label.
Key sources to check:
States run Medicaid formularies with their own prior-auth checklists. Many states now review GLP-1 coverage for obesity or OSA separately; your prescriber’s office can look up the state preferred drug list and submit the matching form.
How Manufacturer Programs Change The Math
Two sets of programs can reduce your bill: insurance-linked savings cards and cash-pay vial pricing through the maker’s pharmacy network.
Commercial Savings Cards ($25 Floor On Many Fills)
For people with commercial or employer coverage, the official savings offer can bring the member share down to as low as $25 when the drug is on your plan and prior auth passes. Eligibility excludes government programs. Activation happens online, and the card runs at the pharmacy with each fill. See the official portal here: Zepbound Savings Card.
Cash-Pay Vials Through LillyDirect
For those without coverage, or when a plan excludes GLP-1 weight-loss use, LillyDirect sells single-dose vials at flat prices. As of this year, the starter dose lists near $349 per month, while maintenance strengths run about $499 when you refill on the program’s schedule. Eli Lilly announced expanded vial strengths and the flat-price structure in press and trade releases, tying access to its direct pharmacy channel.
You can read the manufacturer announcement here: Lilly vial pricing update.
Zepbound Cost With Coverage: A Closer Look
Let’s break common plan designs into plain math.
Flat Copay Plan
Your ID card shows a specialty tier copay (say, $150). If the savings card applies, the register can drop to $25 and the card pays the rest up to a monthly maximum. If your plan excludes the medication, the card won’t run and you’ll either pay cash or use a self-pay program.
Coinsurance Plan
If the benefit sets 30% coinsurance and the allowed cost after plan discounts is $950 this month, your share is $285. A PBM copay-cap add-on can trim this to roughly $200. A manufacturer card may further reduce what you hand over, up to the card’s monthly limit.
High-Deductible Plan
Before meeting the deductible, your share is the allowed cost. At $950 allowed, you owe $950 until you hit the annual deductible. Once met, you pay the listed copay or coinsurance, and a savings card can apply.
Formulary And Prior-Auth Realities
Insurers update policies midyear. Some national carriers now list tirzepatide for weight management on formularies with prior auth, drug-quantity limits, and re-auth timing tied to weight-loss response. Others exclude the brand for weight management but still cover the OSA label with separate criteria. Examples include published drug-quantity and prior-auth policies from large carriers and pharmacy benefit managers.
What Your Prescriber Can Submit
- Diagnosis and BMI meeting labeled use
- Baseline weight and plan to monitor response
- Current meds and prior attempts with nutrition/activity support
- Any secondary labeled use (such as OSA) if applicable
Zepbound Cost Without Coverage
Cash price for pens at retail tends to sit near a four-figure range. Drug-pricing sites list common fills around $995–$1,300 depending on strength and pharmacy. That’s where direct-to-manufacturer cash programs help: vials through the maker’s channel list at $349–$499 when you stick to the refill window.
Picking The Right Fill Channel
Where you send the prescription matters. Specialty pharmacies often understand copay cards and caps better than big-box counters and can process prior-auth follow-ups faster. For cash vials, the direct manufacturer pharmacy avoids third-party markups and locks in the flat price.
Real-World Scenarios And Estimated Bills
These examples show how the pieces fit together. Your numbers will vary, but the structure stays the same.
| Scenario | Assumptions | Estimated Monthly Cost |
|---|---|---|
| Large Employer With Copay Cap | Covered; prior auth approved; PBM add-on sets max member share at ~$200; savings card active | $25–$200 depending on cap and card terms |
| High-Deductible, Early Year | Covered after deductible; allowed cost ~$950; savings card applies | $950 until deductible met, then $25–$200 |
| Plan Excludes Weight-Loss Use | Weight-loss indication excluded; OSA not documented | $349–$499 via manufacturer vials; $995–$1,300 retail cash |
| Medicare Part D For OSA | OSA diagnosis documented; plan lists the drug for that labeled use with PA | $0–$200 depending on plan design and the Part D cap mechanics |
| State Medicaid With PDL Coverage | State PDL covers the brand for obesity or OSA with PA | $0–$50 copay range |
How Dose Changes Affect The Bill
Many start at a low weekly dose and step up. Coinsurance plans can climb with each step if the allowed cost rises. Flat cash vial programs hold steady at the posted price if you refill on the schedule, even as the dose increases within the vial lineup.
Steps To Bring Your Cost Down This Month
1) Confirm The Exact Indication On The Script
If you qualify for the OSA label, that can unlock coverage on plans that exclude weight-loss use. Ask your prescriber to align the script and documentation with the labeled use that applies to you.
2) Send PA Before You Shop Pharmacies
A clean prior-auth beats price-hunting. Have your prescriber submit with BMI, baseline weight, comorbidities, and a clear plan for monitoring response.
3) Use The Official Savings Card If Eligible
Activate it online and present it with your insurance card at pickup: Zepbound Savings Card.
4) Ask Your Plan Or PBM About A Copay Cap
Many employers opt into add-ons that cap your monthly share near $200 for covered GLP-1s. If your employer offers it, enrollment is handled on the plan side and applies automatically at the pharmacy once active.
5) Consider Cash-Pay Vials If Excluded
If your plan excludes the brand for weight management and you don’t qualify under another label, the manufacturer’s direct program can beat retail cash by a wide margin. See the press update here: Lilly vial pricing update.
What Official Sources Say About Coverage Rules
The FDA cleared tirzepatide for chronic weight management in adults with obesity or overweight with a related condition, and later for moderate-to-severe obstructive sleep apnea in adults with obesity. These labeled uses shape coverage paths across public and private plans:
Insurers and PBMs publish policy bulletins and prior-auth forms that lay out the clinical criteria and refill limits. Examples include Cigna’s prior-auth and drug-quantity policies and Caremark prior-auth forms that name tirzepatide for weight management and distinguish vial coverage from direct manufacturer programs.
How To Read Pharmacy Quotes
When a pharmacy quotes a price, ask whether it’s the plan’s allowed cost, a retail cash number, or a manufacturer program price. The difference can be hundreds of dollars. If the number looks off, ask the pharmacy to rerun the claim with your savings card and verify that prior auth has posted.
Frequently Missed Savings
- Wrong channel: A retail pen price was quoted even though your prescriber intended a direct-to-manufacturer vial.
- Card not applied: The pharmacy processed the plan but not the savings card, so the full copay showed up.
- Old PA expired: Many plans require a re-auth every six to twelve months tied to weight-loss response. Set a reminder before the window closes.
Bottom Line On What You’ll Pay
If your plan covers the drug for a labeled use and you can use the savings card, a monthly spend between $25 and $200 is common. If your plan excludes it for weight management and no other labeled use applies, the direct vial cash price of $349–$499 generally beats pharmacy cash. Retail pens without programs often land near $1,000 per month.
Source Notes
This guide references public FDA announcements on both indications and the manufacturer’s pricing updates for its direct pharmacy channel. It also reflects published policy bulletins and prior-auth materials from major carriers and PBMs, along with widely cited retail cash ranges from drug-pricing trackers.
Data points were verified against FDA press materials and current manufacturer pages, plus insurer/PBM policy documents. Links above open relevant pages directly.